Latest Tax Rebates News

PlaySide Studios reversed a prior-year loss with a 13% revenue increase to $54.9 million and a 144% jump in net profit to $5.4 million, driven by strong Original IP sales and a strategic cost restructure.

ReNerve Limited delivered its strongest sales quarter ever with $211,000 in revenue, boosted by new distribution deals in Asia-Pacific and a $5 million funding facility to underpin growth.

Wide Open Agriculture (ASX: WOA) is executing a major strategic pivot by closing its German production site and transitioning to a capital-light contract manufacturing model to improve economics and scale lupin protein production.

Nyrada has dosed the first patient in its Phase IIa trial of Xolatryp targeting heart attack recovery, while strengthening its cash reserves and receiving a US patent allowance for its lead drug.

Biotron has received pivotal regulatory feedback from the European Medicines Agency ruling out a Hybrid Marketing Authorisation for SedRx, prompting plans for pivotal clinical trials. The company also advances its lead antiviral candidate BIT-HBV001 against Hepatitis Delta Virus and appoints a new chairman.

Impact Minerals (ASX:IPT) has received a $310,000 Research and Development tax rebate for FY2025, supporting its Lake Hope High Purity Alumina project and investment in Alluminous Pty Ltd.

Lumos Diagnostics has received a A$709,837 cash refund from the Australian Government’s R&D Tax Incentive, bolstering its investment in proprietary point-of-care diagnostic technologies.

FBR Limited secured its first overseas Mantis welding robot sale, launched the Firehawk refractory robot, and expanded its Wall as a Service footprint in Victoria, while navigating a cash balance under $700,000.

Recce Pharmaceuticals bolsters its clinical and commercial pipeline with a $5.3 million AUD R&D tax rebate, a second U.S. Army research agreement for its RECCE 327 Gel, and a key patent granted in Brazil, while progressing Phase 3 trials in Indonesia.

Environmental Clean Technologies (ASX: ECT) has advanced its PFAS remediation technology with a scalable high-voltage system achieving 1,000°C without additives, expanded its Flash Joule Heating licence to water treatment adsorbents, and formed an expert Advisory Board to accelerate commercialisation.

Artrya has fully integrated its Salix platform at Tanner Health, is preparing two more US sites for launch, and is finalising FDA submission for its Coronary Flow module, backed by a strong cash position of $76.6 million.

Mont Royal Resources is on track to release an updated Preliminary Economic Assessment for its Ashram Rare Earths project in May, with a promising geological review highlighting the BD-Zone as a key area for resource expansion. The company also secured a strategic non-binding MOU with Saguenay Port Authority and extended funding for critical infrastructure.